comprehensive -WSS

comprehensive

author：entertainment 2025-09-09 19:31:24 - browse：93112

The Amgen booth at ESMO in Madrid. Andrew Joseph/STAT

MADRID — A novel type of immunotherapy from Amgen generated strong response rates in patients with advanced small cell lung cancer, results that could lead to the approval of the drug.

The data, reported here Friday at the annual meeting of European Society for Medical Oncology, come from a Phase 2 trial of the drug, called tarlatamab. But they drew greater interest because Amgen has described the study as “potentially registrational,” and the trial results were also published Friday in the New England Journal of Medicine.

“It’s a single arm study, but the results are amazing,” said Silke Gillessen, the scientific chair of ESMO 2023 and an oncologist at the Oncology Institute of Southern Switzerland, noting that advances in small cell lung cancer have been slow to come.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： The history of OxyContin, told through Purdue Pharma documents

WSS

R1 RCM gets $5.8 billion buyout offer from private equity firm

Medicare inequities exacerbate Puerto Rico’s health disparities

Faced with fears of OxyContin misuse, sales reps touted its safety

An innovative path out of biotech’s “valley of death”

Neurocrine Biosciences, biotech based in San Diego, joins PhRMA

Dario to buy mental health app maker Twill in cash and stock deal

hotspot

comprehensive

leisure time

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

After John Oliver segment, STAT readers share their opioid

Cancer drug shortages should be causing more outrage

Who are the detained American citizens released from prison in Iran?

Affirmative action in medical school literally saved lives

He's a Nobel laureate. Critics say he was misleading on Covid

Trump demands the U.S. pay no more for drugs than other countries … again

With competition flaring, obesity drug hits goal in liver disease study

Hepatitis C has a cure — but many Americans still lack access to it

Faced with fears of OxyContin misuse, sales reps touted its safety

hotspot

Faced with fears of OxyContin misuse, sales reps touted its safety

Trump, Nauta plead not guilty to new classified docs charges but De Oliveira still not arraigned

Genentech weighs delaying cancer therapy after drug pricing law

Listen: Your guide to Wegovy's blockbuster heart study

Target recalls 2.2 million additional candles due to laceration, burn hazards

Iran moves toward freeing 5 American citizens who had been imprisoned, in rare deal

knowledge

entertainment

Wikipedia

hotspot